newsfilter
← Latest News
GlobeNewswire·

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Initial Data from Friedreich Ataxia Phase 1 Trial of DT-216 Expected in the Fourth Quarter of 2022 Strong Financial Position with $359.4 Million in Cash and Securities to Support Multi-Year Operating Runway CARLSBAD, Calif., Aug. 08, 2022 (GLOBE